Brown Recluse Spider Bite Mediated Hemolysis: Clinical Features, a Possible Role for Complement Inhibitor Therapy, and Reduced RBC Surface Glycophorin A as a Potential Biomarker of Venom Exposure

Eric A. Gehrie; Hui Nian; Pampee P. Young

doi:10.1371/journal.pone.0076558

Loading metrics

Open Access

Peer-reviewed

Research Article

Brown Recluse Spider Bite Mediated Hemolysis: Clinical Features, a Possible Role for Complement Inhibitor Therapy, and Reduced RBC Surface Glycophorin A as a Potential Biomarker of Venom Exposure

Eric A. Gehrie,

Affiliation Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
⨯
Hui Nian,

Affiliation Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
⨯
Pampee P. Young

* E-mail: pampee.young@vanderbilt.edu

Affiliations Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, Tennessee Valley Veterans Affairs Hospital, Nashville, Tennessee, United States of America
⨯

Brown Recluse Spider Bite Mediated Hemolysis: Clinical Features, a Possible Role for Complement Inhibitor Therapy, and Reduced RBC Surface Glycophorin A as a Potential Biomarker of Venom Exposure

Eric A. Gehrie,
Hui Nian,
Pampee P. Young

Published: September 27, 2013
https://doi.org/10.1371/journal.pone.0076558

About the Authors

Eric A. Gehrie

Affiliation Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

Hui Nian

Affiliation Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

Pampee P. Young

* E-mail: pampee.young@vanderbilt.edu

Affiliations Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, Tennessee Valley Veterans Affairs Hospital, Nashville, Tennessee, United States of America

Competing Interests

The authors have read the journal's policy and have the following conflicts: 1) The study was funded in part by a grant from Alexion Pharmaceuticals, the manufacturer of eculizumab, to EG and PPY. This does not alter the authors' adherence to all of the PLOS ONE policies on sharing data and materials. Dr. HN has declared that no competing interest exists for her contribution.

Author Contributions

Conceived and designed the experiments: EG PYY. Performed the experiments: EG. Analyzed the data: EG PYY HN. Contributed reagents/materials/analysis tools: EG PYY HN. Wrote the manuscript: EG PYY HN.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Venoms
Is the Subject Area "Venoms" applicable to this article?

Thanks for your feedback.
Glycophorins
Is the Subject Area "Glycophorins" applicable to this article?

Thanks for your feedback.
Spiders
Is the Subject Area "Spiders" applicable to this article?

Thanks for your feedback.
Red blood cells
Is the Subject Area "Red blood cells" applicable to this article?

Thanks for your feedback.
Blood plasma
Is the Subject Area "Blood plasma" applicable to this article?

Thanks for your feedback.
Complement inhibitors
Is the Subject Area "Complement inhibitors" applicable to this article?

Thanks for your feedback.
Charts
Is the Subject Area "Charts" applicable to this article?

Thanks for your feedback.
Complement system
Is the Subject Area "Complement system" applicable to this article?

Thanks for your feedback.